Clinical Trials Browser

Phase 2/3 × Oligometastatic Prostate Cancer × Androgen Antagonists × Clear all

NCT06972511 2025-05-15

Maximal Tumor Eradication for Oligometastatic Prostate Cancer

Phase 2/3 Recruiting

Oligometastatic Prostate Cancer